Keytruda and Hypercoagulation - a phase IV clinical study of FDA data

Summary:

Hypercoagulation is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Diclofenac, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Hypercoagulation when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,403 Keytruda users. Check the latest studies of Keytruda.

What is Hypercoagulation?

Hypercoagulation (increased tendency for clotting of the blood) is found to be associated with 420 drugs and 533 conditions by eHealthMe. Check the latest studies of Hypercoagulation.

On Jan, 12, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 12 people (0.02%) have Hypercoagulation.

Among these 12 people:

How long have people been on Keytruda when they have Hypercoagulation? *

What is the gender of people who have Hypercoagulation when taking Keytruda? *

female: 8.33 %
male: 91.67 %

What is the age of people who have Hypercoagulation when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Hypercoagulation? *

Malignant Neoplasm Progression (cancer tumour came back): 5 people, 41.67%
Dyspnea (difficult or laboured breathing): 4 people, 33.33%
Diarrhea: 3 people, 25.00%
Anaemia (lack of blood): 3 people, 25.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 25.00%
Fatigue (feeling of tiredness): 3 people, 25.00%
Cardiac Failure: 2 people, 16.67%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 2 people, 16.67%
Nausea And Vomiting: 2 people, 16.67%
Drug Hypersensitivity: 2 people, 16.67%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 25.00%
Seasonal Allergy (allergic condition due to certain season): 1 person, 8.33%
Sarcoma Metastatic (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues spreads to other parts): 1 person, 8.33%
Pain: 1 person, 8.33%
Oesophageal Adenocarcinoma Stage Iv (cancer has spread to other parts of the body): 1 person, 8.33%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 8.33%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
Colon Cancer: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Hypercoagulation?

- Check whether Hypercoagulation is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,403 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypercoagulation:

Hypercoagulation (421 drugs)

Browse all the conditions that are associated with Hypercoagulation:

Hypercoagulation (533 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.